Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02710903
Other study ID # 15-0637
Secondary ID 5K23DE025093-025
Status Terminated
Phase N/A
First received
Last updated
Start date May 2016
Est. completion date March 28, 2018

Study information

Verified date September 2019
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A maximum of 220 subjects with a minimum of 25 years will be recruited and examined for this 1-7 visit, up to 35 days research study: Subjects will be genotyped to identify variants of the interleukin-29 (IL29) and interleukin-28B (IL28B) genes and placed in one of the 4 groups: 50 subjects with dominant allelic variants with healthy periodontium, 50 subjects with dominant allelic variants with periodontitis, 50 subjects with IL29 (rs30461) or any of IL28B (rs11083519; rs8105790; rs8099917) single nucleotide polymorphism's (SNP) variants and healthy periodontium, and 50 subjects with IL29 (rs30461) or any of IL28B (rs11083519; rs8105790; rs8099917) SNP variants and periodontitis. Visits will consist of outpatient procedures including oral examinations, oral prophylaxis or periodontal scaling and root planing, collection of gingival crevicular fluid, dental plaque, saliva, and blood samples. Analysis will include salivary DNA isolation and pyrosequencing to determine IL29 and IL28B genotype, mediator analysis of gingival crevicular fluid, dendritic cell differentiation and inflammatory mediator analysis, and whole-genome shotgun sequencing plaque analysis. Clinical outcomes will include measurements of periodontal disease progression and inflammation, such as clinical attachment level (CAL), pocket depth (PD), bleeding on probing (BOP), gingival index (GI), and plaque index (PI).

Primary Objective: To determine the impact of IL29 and IL28B SNP variants on periodontal disease expression and local inflammatory response during stent-induced biofilm overgrowth.

Secondary Objective: To evaluate in vitro the impact of IL29 and IL28B SNP variants on cell-mediated, innate inflammatory response.


Recruitment information / eligibility

Status Terminated
Enrollment 79
Est. completion date March 28, 2018
Est. primary completion date March 13, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria:

- Subjects must have read, understood and signed an informed consent form in English.

- Subjects must be able and willing to follow study procedures and instructions in English.

- Subjects must be non-Hispanic Caucasian.

- Subjects must be adult males or females with a minimum of 25 years (inclusive).

- Subjects must present with at least 20 teeth in the functional dentition, excluding third molars.

- Subjects must have at least 3 teeth in each posterior sextant.

- Subjects must be in good general health.

- Subjects must present with one of the following four categories to be considered for enrollment:

- Dominant IL28B and IL29 allelic with PD =4mm, no evidence of interproximal CAL, and <20% of sites with BOP.

- Dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD = 5mm, evidence of interproximal CAL, and =20% of sites with BOP.

- IL28B or IL29 SNP variants with PD =4mm, no evidence of interproximal CAL, and <20% of sites with BOP.

- IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD = 5mm, evidence of interproximal CAL, and =20% of sites with BOP

Exclusion Criteria:

- Chronic disease with oral manifestations including diabetes mellitus.

- Current smoker or one that has stopped smoking less than 2 years prior to enrollment.

- Gross oral pathology other than the periodontal disease.

- Treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination.

- Chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, coumadin, non-steroidal anti-inflammatory drugs, aspirin) within one month of the screening examination.

- Ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment).

- Significant organ disease including impaired renal function, heart murmur, history of rheumatic fever or valvular disease, or any bleeding disorder.

- Infectious diseases such as hepatitis, HIV or tuberculosis.

- Anemia or other blood dyscrasias.

- Anticoagulant therapy or drugs, such as heparin or warfarin.

- Severe unrestored caries, or any condition that is likely to require antibiotic treatment over the trial.

- Pregnant, or expect to become pregnant within the next several months.

- Females of child-bearing capacity must be willing to have pregnancy test to confirm they are not pregnant.

- Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Stent-induced biofilm overgrowth
Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in pocket depth (mm) 21 days
Primary Change in clinical attachment level (mm) 21 days
Primary Change in plaque index (0-3) 21 days
Primary Change in bleeding on probing (Yes/No) 21 days
Primary Change in gingival crevicular fluid interleukin-1 beta (GCF IL-1b) 21 days
Primary Change in gingival crevicular fluid prostaglandin E2 (GCF PGE2) 21 days
Primary Change in gingival crevicular fluid interleukin-29 (GCF IL-29) 21 days
Primary Change in gingival crevicular fluid interleukin-28B (GCF IL-28B) 21 days
Primary Change in gingival index (0-4) 21 days
Primary Composition of the microbiota oral flora 21 days
Primary Change in gingival crevicular fluid interleukin-6 (GCF IL-6) 21 days
Secondary Change in interleukin-29 expression in dendritic cells at day 35 35 days
Secondary Change in interleukin-28B expression in dendritic cells at day 35 35 days
See also
  Status Clinical Trial Phase
Completed NCT04712630 - Non-Incised Papillae Surgical Approach (NIPSA) With and Without Graft N/A
Completed NCT06127069 - Treatment of Residual Pockets in Periodontal Patients Using an Oscillating Chitosan Device N/A
Completed NCT04964167 - Indocyanine-green Mediated Photosensitizer VS Aloe Vera Gel: Adjunct Therapy to Scaling and Root Planing in Patients With Chronic Periodontitis Phase 4
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Recruiting NCT03997552 - NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration N/A
Completed NCT05530252 - Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis Phase 4
Completed NCT04881357 - Antiplaque/Antigingivitis Effect of Lacer Oros Integral N/A
Recruiting NCT03790605 - A Clinical Trial to Study the Effect of a Drug, Curcumin in Patients With Periodontitis Phase 3
Enrolling by invitation NCT04971174 - Outcomes of Periodontal Regenerative Treatment
Not yet recruiting NCT05568290 - Interleukin-38 Levels in Individuals With Periodontitis
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Recruiting NCT03997578 - Non-incised Papillae Surgical Approach (NIPSA) and Connective Tissue Graft Plus Emdogain for Periodontal Defects N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Enrolling by invitation NCT04956211 - Periodontal Treatment and Ischemic Stroke N/A
Recruiting NCT05971706 - Ozone Application in Periodontal Treatment N/A
Recruiting NCT06099574 - A Study on the Oral Health Status of Pregnant Women With Gestational Diabetes and Its Correlation With Oral Flora
Completed NCT04402996 - Meteorin-like Levels in Individuals With Periodontitis
Active, not recruiting NCT05311657 - Oral Health and Severe COPD
Not yet recruiting NCT06453278 - (DDS) in India: a Screening Tool to Identify Prediabetes and Undiagnosed Type 2 Diabetes in Dental Settings
Not yet recruiting NCT05643287 - The Effect of Time on the Outcome of Periodontal Treatment. N/A